详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [2]Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, China. [3]Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

出处：

DOI：

ISSN：

关键词： immunotherapy radiotherapy combination immunecheckpoints non-smallcelllungcancer

摘要：

Lately, the success of ICIs has drastically changed the landscape of cancer treatment, and several immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration (FDA) for advanced non-small cell lung cancer (NSCLC). However, numerous patients are resistant to ICIs and require additional procedures for better efficacy results. Thus, combination therapy is urgently needed to strengthen the anti-tumor immunity. A variety of preclinical and clinical studies combining ICIs with radiotherapy (RT) have demonstrated that the combination could induce synergistic effects, as RT overcomes the resistance to ICIs. However, the underlying mechanism of the synergistic effect and the optimal arrangement of the combination therapy are indecisive now. Hence, this review was conducted to provide an update on the current clinical trial results and highlighted the ongoing trials. We also discussed the optimal parameters in clinical trials, including radiation dose, radiation fractionation, radiation target field, and sequencing of combination therapy. In this review, we found that combination therapy showed stronger anti-tumor immunity with tolerable toxicities in clinical trials. However, the best combination mode and potential biomarkers for the target patients in combination therapy are still unclear.© The Author(s) [2019]. Published by Oxford University Press on behalf of West China School of Medicine & West China Hospital of Sichuan University.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

无

最新[2023]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer. [2]Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors. [3]放疗联合免疫治疗非小细胞肺癌：前沿学术问题专家交流共识 [4]Chitosan- and hyaluronic acid-based nanoarchitectures in phototherapy: Combination cancer chemotherapy, immunotherapy and gene therapy [5]Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma. [6]Gemcitabine Improves Suppressive Immune Microenvironment Induced by Long-Term Treatment with EGFR-TKIs: Implications for Combination Chemotherapy and Immunotherapy [7]ICBcomb: a comprehensive expression database for immune checkpoint blockade combination therapy [8]Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy [9]Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges. [10]Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation